


4th International Electronic Conference on Medicinal Chemistry

1-30 November 2018 chaired by Dr. Jean Jacques Vanden Eynde



DBAASP Special prediction as a tool for the prediction of antimicrobial potency against particular target species

Boris Vishnepolsky ^{1,*}, Maya Grigolava ¹, George Zaalishvili ², Margarita Karapetian ² and Malak Pirtskhalava ^{1,*}

¹ I.Beritashvili Center of Experimental Biomedicine, Gotua str. 14, Tbilisi 0160, Georgia
 ² Agricultural University of Georgia, 240 David Aghmashenebeli Alley, Tbilisi 0159, Georgia

* Corresponding authors: b.vishnepolsky@lifescience.org.ge; m.pirtskhalava@lifescience.org.ge



DBAASP Special prediction as a tool for the prediction of antimicrobial potency against particular target species


Graphical Abstract

Performances of Predictive models for

Staphylococcus aureus 25923

Bacillus subtilis

Human Erythrocytes









Abstract

Antimicrobial peptides (AMPs) have been identified as a potentially new class of antibiotics. There are a lot of computational methods of AMP prediction. Although most of them can predict antimicrobial potency against any microbe (microbe is not identified) with rather high accuracy, prediction quality of these tools against particular bacterial strains is low [1,2]. Special prediction is a tool for the prediction of antimicrobial potency of peptides against particular target species with high accuracy. This tool is included into the Database of Antimicrobial Activity and Structure of Peptides (DBAASP, <u>https://dbaasp.org [3]</u>). In this presentation we describe this tool and predictive models for some Gram positive bacterial strains (Staphylococcus aureus ATCC 25923 and Bacillus subtilis) and a model for the prediction of hemolytic activity. Predictive model for Gram negative Escherichia coli ATCC 25922 was presented earlier [2,4]. Special prediction tool can be used for the design of peptides being active against particular strain. To demonstrate the capability of the tool, peptides predicted as active against E-coli ATCC 25922 and Staphylococcus aureus ATCC 25923 have been synthesized, and tested in vitro. The results have shown the justification of using special prediction tool for the design of new AMPs

Keywords: Antimicrobial peptides; AMP prediction; Design of AMPs





- The problem of bacterial resistance to antibiotics is one of the important tasks in microbiology.
- Antimicrobial peptides in most cases act on the membrane of bacteria, which complicates the development of resistance of microbes to them.
- Therefore, AMPs are good candidates for new antibiotics





- Currently, antimicrobial peptides are being actively studied. The database DBAASP [3] consists of more than 11 500 AMPs and their number is constantly increasing.
- Nevertheless, antimicrobial peptides are rarely used in clinical practice.
- There are several reasons that prevent the active use of AMP as antibiotics:
 - 1. They can be available for the action of proteases for a short time and the peptides do not show antimicrobial activity.
 - 2. Many AMPs have hemolytic or cytotoxic activity.
 - 3. Their high cost price.





- Despite this, the design and synthesis of new peptides actively continues (more than 75% of peptides in DBAASP are synthetic.) and some of them are in clinical trial.
- For task-oriented design of new AMPs, tools for prediction of antimicrobial activities of peptides are needed.
- At the moment many AMP prediction tools are available .
- Most of these tools can only predict if a peptide has any antimicrobial activity, but cannot predict antimicrobial potency against particular strains [1,2]





- So one of the main problems in the design of new peptides is the lack of effective predictive models capable of showing high performance when designing new amino acid sequences with a high therapeutic effect against specific strains of bacteria.
- Special prediction (SP) is developed as a tool for the prediction of antimicrobial potency of peptides against particular target species and therefore can be considered as an attempt to resolve the above-mentioned problems







- Predictive models of SP were based on clustering of peptides into groups of peptides (clusters) according to their physical-chemical properties.
- The following 9 characteristics are used to describe the PCP of peptide:
 - Hydrophobic moment (M)
 - Hydrophobicity (H)
 - Charge (C)
 - Isoelectric Point (I)
 - Penetration Depth (D)
 - Orientation of Peptides relative to the surface of membrane (O)
 - Propensity to Disordering (R)
 - Linear Moment (L)
 - In vitro aggregation (A)
- Each optimized cluster is defined by a subset of these characteristics and intervals of the values of the corresponding characteristics





Conditions of creation training and test sets for the predictive models

- Positive set is formed on the basis of condition MIC <25 mg/ml
- Negative set is formed on the basis of condition >100 mg/ml
- Sets were performed with the following restrictions:
 - Sequence length 10-16 amino acids
 - Without intra-chain bonds
 - Without unusual amino acids





- Detailed description of the algorithm relied on which the predictive model for Escherichia coli ATCC 25922 has been developed, can be found here [2,4]
- Current presentation describes predictive models for some Gram positive (Staphylococcus aureus ATCC 25923 and Bacillus subtilis) bacterial strains and a model for the prediction of hemolytic activity, which are based on the same algorithm as for Escherichia coli ATCC 25922





Predictive model for Staphylococcus aureus 25923

Optimized clusters obtained for peptides active against Staphylococcus aureus 25923

O – Orientation of Peptides The properties which determine a relative to the surface of space of characteristics where clusters have appeared R – Propensity to Disordering 17% HIDL Percentage of the peptides of positive training set **IDORL** which form Cluster 1 Percentage of the peptides 71% of positive training set which form Cluster 2 Percentage of the peptides of positive training set which are not clusterized



H – Hydrophobicity I – Isoelectric Point **D** – Penetration Depth

membrane


L – Linear Moment



Predictive model for Staphylococcus aureus 25923

Sensitivity, Specificity and Accuracy for training and test sets

Training set - 140 peptides in positive set and 140 peptides in negative set **Test set** – 37 peptides in positive set and 37 peptides in negative set










Predictive model for Bacillus subtilis

Optimized clusters obtained for peptides active against Bacillus subtilis








Predictive model for Bacillus subtilis

Sensitivity, Specificity and Accuracy for training and test sets

Training set - 100 peptides in positive set and 100 peptides in negative set **Test set** – 30 peptides in positive set and 30 peptides in negative set








Predictive model for hemolytic activity prediction

Optimized clusters obtained for peptides nonactive against Human erythrocytes



The properties which determine a space of characteristics where clusters have appeared

Percentage of the peptides

Percentage of the peptides

Percentage of the peptides

of positive training set

of positive training set

of positive training set
which form Cluster 3
Percentage of the peptides
of positive training set
which are not clusterized

which form Cluster 2

which form Cluster 1

- M Hydrophobic moment
- H Hydrophobicity
- C Charge
- I Isoelectric Point
- O Orientation of Peptides relative to the surface of membrane
- R Propensity to Disordering
- L Linear Moment (L)
- A In vitro aggregation (A)



4th International Electronic Conference on Medicinal Chemistry 1-30 November 2018

sponsors:






Predictive model for hemolytic activity prediction

Sensitivity, Specificity and Accuracy for training and test sets

Training set - 120 peptides in positive set and 120 peptides in negative set **Test set** – 43 peptides in positive set and 43 peptides in negative set





4th International Electronic Conference on Medicinal Chemistry 1-30 November 2018



sponsors:

Screenshot of SP Page of DBAASP (https://dbaasp.org/prediction)


	_
Pseudomonas aeruginosa ATCC 27853	*
Staphylococcus aureus ATCC 25923	
Human erythrocytes The species can be selected from menu	
Bacillus Subtilis	

Paste sequence(s) in FASTA format ('+' can be added to the end of the sequence in the case of C-Terminal amidation) :

>2 KLALKLALK/ >3	KARRWQWRMKKLGA ALKAALKLA+ JIGAVLKVLTTG		
	The results are presented as positive or ne	gative predictive values (PPV and NPV). Submit
ID	Strain Type	Class	Predictive value
1	Staphylococcus aureus ATCC 25923	Not Active	0.80
1	Bacillus Subtilis	Active	0.81
0	Ci. 1. 1	A	0.00
2	Staphylococcus aureus ATCC 25923	Active	0.82
2	Bacillus Subtilis	Active	0.81
3			
	Staphylococcus aureus ATCC 25923	Not Active	0.80



4th International Electronic Conference on Medicinal Chemistry 1-30 November 2018





pharmaceuticals

Peptide design

- Peptides were designed by the following principles:
 - Length of peptides is 13, based on the data of most frequent peptide lengths in DBAASP and requirement of low cost.
 - Sequences were selected from randomly generated amino acid sequences according to the requirements: the values of physical-chemical properties should correspond to statistically more reliable clusters obtained for Escherichia coli ATCC, Staphylococcus aureus 25923, and Human erythrocytes
 - 22 and 12 sequences have been generated as having potential against Escherichia coli ATCC 25922 and Staphylococcus aureus 25923, respectively.
 24 sequences have been created as non-active against Human erythrocytes





- Peptides have been synthesized relying on generated sequences
- Susceptibilities of Escherichia coli ATCC 25922, Staphylococcus aureus 25923 and Human erythrocytes against synthesized peptides were tested *in vitro*
- Peptides were considered as active and non-active against the corresponding bacterial strains if they have MIC<50 and >100 mg/ml correspondingly
- Peptides are considered as non-hemolytic if they have <10% of hemolytic activity of 0.1% Trilton X-100 which is use as reference, at peptides' concentration 100 mg/ml





In vitro test results

- 21 from 22 predicted peptides show activity against Escherichia coli ATCC 25922
- 10 from 12 predicted peptides show activity against Staphylococcus aureus 25923
- 22 from 24 predicted peptides do not show hemolytic activity.





Conclusions

- SP tool is available online in DBAASP website (<u>https://dbaasp.org</u>)
- In-silico test of SP predictive models shows accuracy about 0.8 for Staphylococcus aureus 25923, Bacillus subtilis, and for hemolytic activity prediction.
- The tests show that 95% and 80% of the peptides, designed as active against Escherichia coli ATCC 25922 and Staphylococcus aureus correspondingly, show also high antimicrobial activity *in vitro*.
- 92% of the peptides, *de novo* designed as non-active against Human erythrocytes do not show hemolytic activity *in vitro*
- SP tool can be satisfactorily used for the development of peptide-based antiinfectives





Acknowledgments

This work was supported by International Science and Technology Center provided through National Institute of Allergy and Infectious Diseases / National Institutes of Health (G-2102) and Shota Rustaveli National Science Foundation (DI-2016-9)











References

- 1. Vishnepolsky B and Pirtskhalava M. Comment on: 'Empirical comparison of web-based antimicrobial peptide prediction tools' *Bioinformatics.,* 2018, in press.
- 2. Vishnepolsky B, Gabrielian A, Rosenthal A, Darrell EH, Tartakovsky M, Managadze G, Grigolava M, Makhatadze GI, and Pirtskhalava M. Predictive Model of Linear Antimicrobial peptides Active against Gram-Negative Bacteria. J. Chem. Inf. Model. 2018, 58, 1141.
- 3. Pirtskhalava M, Gabrielian A, Cruz P, Griggs HL, Squires RB, Hurt DE, Grigolava M, Chubinidze M, Gogoladze G, Vishnepolsky B, Alekseev V, Rosenthal A, and Tartakovsky M. DBAASP v.2: an Enhanced Database of Structure and Antimicrobial/Cytotoxic Activity of Natural and Synthetic Peptides. *Nucl. Acids Res.*, 2016, 44 (D1), D1104-D1112.
- B. Vishnepolsky; M. Grigolava; G. Zaalishvili; M. Karapetian; M. Pirtskhalava, Design and *in vitro* Testing of New Antimicrobial Peptides Based on QSAR Modelling. In Proceedings of the *2nd Int. Electron. Conf. Med. Chem.* 01-30 November 2016; MDPI AG, 2016, A031.



